Athersys and Cleveland Clinic Foundation Collaborate on Drug Target Project | GenomeWeb

NEW YORK, March 9 - Athersys will use its Random Activation of Gene Expression technology in a collaboration with the Cleveland Clinic Foundation to discover and validate drug targets for cancer and inflammation cell signaling pathways, the company said Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.